Arcus Biosciences Inc
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 9.4% | 16.1% | 2.1% | 5.1% | – | 11.5% | – | 1.3% | 7.7% | 9.1% | 11.8% | – | – | |
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 92.3% | 90.9% | 88.2% | 100.0% | 94.0% | |
| 256.3% | 300.0% | 75.2% | 294.9% | 256.3% | 388.5% | 435.7% | 86.9% | 542.3% | 366.7% | 717.6% | 275.6% | 424.8% | |
| 93.8% | 93.5% | 22.1% | 76.9% | 62.5% | 107.7% | 100.0% | 18.1% | 103.8% | 78.8% | 170.6% | 58.5% | 90.6% | |
| 350.0% | 393.5% | 111.0% | 371.8% | 318.8% | 496.2% | 535.7% | 105.0% | 638.5% | 436.4% | 876.5% | 334.1% | 509.4% | |
| -250.0% | -293.5% | -11.0% | -271.8% | -218.8% | -396.2% | -435.7% | -5.0% | -546.2% | -345.5% | -788.2% | -234.1% | -415.4% | |
| 3.1% | 6.5% | 0.7% | 0.0% | 2.1% | 7.7% | 3.6% | 1.3% | 11.5% | 42.4% | 17.6% | 7.3% | 19.7% | |
| -215.6% | -258.1% | -2.8% | -238.5% | -191.7% | -361.5% | -400.0% | -5.0% | -519.2% | -297.0% | -752.9% | -222.0% | -386.3% | |
| 6.3% | 3.2% | 0.7% | – | – | 3.8% | – | – | – | – | – | – | – | |
| -221.9% | -261.3% | -2.8% | -238.5% | -191.7% | -361.5% | -400.0% | -5.0% | -519.2% | -297.0% | -752.9% | -222.0% | -386.3% | |
| -209.4% | -248.4% | 4.8% | -233.3% | -185.4% | -342.3% | -385.7% | 2.5% | -500.0% | -245.5% | -723.5% | -207.3% | -358.1% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.